Fulgent Genetics Inc
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +175.1% | +895.2% | -1.9% | -3.4% | +61.3% | +689.2% | +82.6% | +8.4% | -10.9% | -1.2% | -0.5% | |
| – | +312.7% | +1,634.8% | -10.7% | -4.4% | -14.5% | +1,312.2% | +16.9% | +2.6% | -19.1% | -30.4% | +55.7% | |
| – | +184.3% | +1,514.9% | -17.8% | +3.8% | +77.6% | +630.7% | +88.6% | -51.8% | +22.6% | -43.4% | -9.0% | |
| – | +184.3% | +9,402.0% | -11.0% | -9.5% | -24.5% | +959.0% | +50.5% | +16.8% | -19.4% | -39.1% | +30.2% | |
| – | +456.8% | +102.5% | -6.7% | +53.2% | +15.4% | +2,734.6% | -29.8% | -47.6% | -23.5% | +34.1% | +18.9% | |
| – | +50.4% | +51.9% | -28.3% | +35.9% | -11.8% | +5,853.4% | -26.0% | -64.9% | +36.1% | +43.9% | +26.5% | |
| – | +152.5% | +152.5% | +16.7% | -11.4% | +33.5% | +367.1% | +54.9% | +58.8% | – | – | – | |
| – | – | – | – | – | – | – | – | +181.0% | -84.6% | +0.0% | +13.7% | |
| – | – | – | – | – | – | – | – | +319.5% | -5.0% | -5.6% | -1.3% | |
| – | +57.3% | +419.1% | -17.9% | -6.2% | +117.8% | +2,092.2% | -13.9% | +3.0% | -12.2% | -11.0% | +17.6% | |
| – | +57.3% | +419.1% | -17.9% | -6.2% | +35.6% | +3,394.9% | -19.1% | -16.3% | -17.1% | -0.2% | +16.6% | |
| – | – | – | – | – | – | +3,539.5% | +39.2% | +25.8% | -80.8% | -63.9% | +4.5% | |
| – | +90.3% | +777.7% | -24.2% | -37.1% | +20.4% | +1,575.4% | -22.6% | +12.7% | -33.5% | +19.6% | +1.6% | |
| – | – | – | – | – | – | – | – | – | -12.1% | -15.9% | -21.5% | |
| – | +205.6% | +958.7% | -0.8% | -3.3% | +58.4% | +587.9% | +103.5% | +9.3% | -10.3% | -0.3% | -1.9% | |
| – | – | – | – | – | – | – | +335.8% | +21.8% | -21.0% | -6.7% | -10.2% | |
| – | -27.8% | +38.4% | +0.4% | +1.3% | +4.1% | +28.6% | +28.8% | 0.0% | -3.8% | +1.5% | +1.8% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.